<DOC>
	<DOCNO>NCT00003245</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irinotecan treating patient recurrent refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Recurrent Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate toxicity irinotecan administer patient recurrent refractory non-Hodgkin 's lymphoma . OUTLINE : Patients stratify disease category ( aggressive v indolent v mantle cell lymphoma ) . Patients aggressive indolent lymphoma stratify refractory ( complete response ( CR ) partial response ( PR ) initial therapy ) v recurrent ( CR PR initial therapy ) ; i.e , follow subcategories use : - Stratum I : Refractory aggressive non-Hodgkin 's lymphoma ( NHL ) - Stratum II : Recurrent aggressive NHL - Stratum III : Refractory indolent NHL - Stratum IV : Recurrent indolent NHL - Stratum V : Mantle cell NHL All patient receive irinotecan intravenously every 21 day . Patients achieve CR PR receive 6 course . Patients may receive bone marrow transplantation least 2 course . Patients follow every 3 month survival . PROJECTED ACCRUAL : This study accrue 18 patient per stratum ; least three patient respond , additional 25 patient accrue total 43 evaluable patient per stratum . The total number accrue 90-215 period approximately 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent refractory nonHodgkin 's lymphoma First relapse require histologic confirmation relapse No CNS metastases No lymphomatous meningitis Measurable disease PATIENT CHARACTERISTICS : Age : 1575 Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : Unless due lymphoma : Platelet count least 100,000/mm^3 Absolute granulocyte count least 1,500/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT great 3 time upper limit normal ( ULN ) ( great 5 time ULN liver involvement ) Renal : Creatinine great 2.0 mg/dL Baseline calcium le 12 mg/dL Cardiovascular : No myocardial infarction within 6 month No congestive heart failure require therapy Other : No history seizures No uncontrolled diabetes mellitus ( i.e. , random blood sugar least 250 mg ) No concurrent severe disease No uncontrolled infection HIV negative No psychoses No prior malignancy except adequately treat basal cell squamous cell skin cancer situ cancer cervix unless surgically treat disease free least 5 year Not pregnant lactate Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow transplantation Chemotherapy : No 2 prior chemotherapy regimen treatment lymphoma No prior irinotecan , topotecan aminocamptothecin At least 3 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy Radiotherapy part combinedmodality therapy count regimen ( see Chemotherapy ) Surgery : Not specify Other : No phenytoin , phenobarbital , antiepileptic prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>